Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Dificid Survey Suggests Good Growth Opportunity

Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Baird analyst said, "Remain OP-rated after analyzing BioTrends'/AMR's third survey into launch of Dificid. This latest LaunchTrends survey goes into the mosaic as another set of datapoints suggesting Dificid has the opportunity to grow steadily and at least meet conservative investor expectations, if OPTR and co-promote partner Cubist (Nasdaq: CBST) continue to execute. Our estimates, recently fine-tuned following OPTR’s Q4-11 update, and our target price are both unchanged, and we continue to like this stock for relatively lower risk small-cap exposure to the biotech/pharma group."

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $12.94 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'